AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada. Show more

150 West 4th Ave, Vancouver, BC, V5Y 1G6, Canada

Biotechnology

Healthcare

Start AI Chat

Market Cap

910M

52 Wk Range

$1.89 - $6.51

Previous Close

$3.22

Open

$3.16

Volume

4,703,134

Day Range

$2.96 - $3.18

Enterprise Value

1.376B

Cash

495.7M

Avg Qtr Burn

-52.59M

Insider Ownership

22.98%

Institutional Own.

37.86%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Bebtelovimab (LY-CoV1404) Details COVID-19	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bamlanivimab (LY-CoV555) Details COVID-19	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABCL635 Details Moderate-to-severe vasomotor symptoms (VMS) or "hot flashes"	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ABCL575 Details Moderate-to-severe atopic dermatitis (AD)	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.